
Takeda to return molecules/ products for Japan to Amgen
pharmafile | June 27, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Amgen, Cancer, Japan, Takeda Pharmaceutical, drug development, drug trial
Japanese firm Takeda Pharmaceutical (TSE: 4502) said it will return the rights to develop and market multiple molecules/ products from Amgen’s (Nasdaq: AMGN) pipeline for the Japanese market.
Under the revised agreement the company will return rights for the molecules AMG403 and AMG386, effective immediately, the company said in a statement.
Takeda and Amgen will continue to collaborate on remaining molecules/ products for the Japanese market, including Vectibix (panitumumab), a leading treatment for unresectable advanced or recurrent colorectal cancer, Takeda said.
Phil Rowlands, interim head, oncology therapeutic area unit, Takeda, said: “Through our work with Amgen, we have successfully delivered Vectibix to the Japanese patients facing a challenging diagnosis while continuing to build our scientific understanding of novel treatment pathways. We look forward to continuing our scientific discovery and to building a portfolio of innovative medicines through our ongoing collaboration with Amgen.”
No financial details were disclosed.
Anjali Shukla
Related Content

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Custom Pharmaceuticals launches new company for drug product development
Customs Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO), has launched Centrix Pharma Solutions, …

BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …






